vs
Side-by-side financial comparison of Weyerhaeuser (WY) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.3B vs $1.7B, roughly 1.3× Weyerhaeuser). Zoetis runs the higher net margin — 26.6% vs 9.0%, a 17.5% gap on every dollar of revenue. On growth, Weyerhaeuser posted the faster year-over-year revenue change (12.1% vs 2.9%). Over the past eight quarters, Zoetis's revenue compounded faster (-2.1% CAGR vs -5.6%).
The Weyerhaeuser Company is an American timberland company which owns approximately 10,400,000 acres of timberlands in the U.S., and manages an additional 14,000,000 acres of timberlands under long-term licenses in Canada. The company has manufactured wood products for over a century. It operates as a real estate investment trust (REIT).
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
WY vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.7B | $2.3B |
| Net Profit | $156.0M | $601.0M |
| Gross Margin | — | 71.7% |
| Operating Margin | 14.3% | — |
| Net Margin | 9.0% | 26.6% |
| Revenue YoY | 12.1% | 2.9% |
| Net Profit YoY | 110.8% | -0.2% |
| EPS (diluted) | $0.22 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.7B | $2.3B | ||
| Q4 25 | $1.5B | $2.4B | ||
| Q3 25 | $1.7B | $2.4B | ||
| Q2 25 | $1.9B | $2.5B | ||
| Q1 25 | $1.8B | $2.2B | ||
| Q4 24 | $1.7B | $2.3B | ||
| Q3 24 | $1.7B | $2.4B | ||
| Q2 24 | $1.9B | $2.4B |
| Q1 26 | $156.0M | $601.0M | ||
| Q4 25 | $74.0M | $603.0M | ||
| Q3 25 | $80.0M | $721.0M | ||
| Q2 25 | $87.0M | $718.0M | ||
| Q1 25 | $83.0M | $631.0M | ||
| Q4 24 | $81.0M | $581.0M | ||
| Q3 24 | $28.0M | $682.0M | ||
| Q2 24 | $173.0M | $624.0M |
| Q1 26 | — | 71.7% | ||
| Q4 25 | 10.4% | 70.2% | ||
| Q3 25 | 11.9% | 71.5% | ||
| Q2 25 | 17.3% | 73.6% | ||
| Q1 25 | 19.0% | 72.0% | ||
| Q4 24 | 17.8% | 69.5% | ||
| Q3 24 | 14.9% | 70.6% | ||
| Q2 24 | 20.8% | 71.7% |
| Q1 26 | 14.3% | — | ||
| Q4 25 | 16.3% | 31.9% | ||
| Q3 25 | 7.2% | 37.0% | ||
| Q2 25 | 9.4% | 36.7% | ||
| Q1 25 | 10.2% | 36.5% | ||
| Q4 24 | 8.3% | 31.6% | ||
| Q3 24 | 4.6% | 36.6% | ||
| Q2 24 | 13.9% | 33.0% |
| Q1 26 | 9.0% | 26.6% | ||
| Q4 25 | 4.8% | 25.3% | ||
| Q3 25 | 4.7% | 30.0% | ||
| Q2 25 | 4.6% | 29.2% | ||
| Q1 25 | 4.7% | 28.4% | ||
| Q4 24 | 4.7% | 25.1% | ||
| Q3 24 | 1.7% | 28.6% | ||
| Q2 24 | 8.9% | 26.4% |
| Q1 26 | $0.22 | $1.42 | ||
| Q4 25 | $0.11 | $1.37 | ||
| Q3 25 | $0.11 | $1.63 | ||
| Q2 25 | $0.12 | $1.61 | ||
| Q1 25 | $0.11 | $1.41 | ||
| Q4 24 | $0.10 | $1.29 | ||
| Q3 24 | $0.04 | $1.50 | ||
| Q2 24 | $0.24 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $299.0M | — |
| Total DebtLower is stronger | $372.0M | — |
| Stockholders' EquityBook value | $9.4B | — |
| Total Assets | $16.4B | — |
| Debt / EquityLower = less leverage | 0.04× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $299.0M | — | ||
| Q4 25 | $464.0M | — | ||
| Q3 25 | $401.0M | $2.1B | ||
| Q2 25 | $592.0M | $1.4B | ||
| Q1 25 | $560.0M | $1.7B | ||
| Q4 24 | $684.0M | $2.0B | ||
| Q3 24 | $877.0M | $1.7B | ||
| Q2 24 | $997.0M | $1.6B |
| Q1 26 | $372.0M | — | ||
| Q4 25 | $5.6B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $5.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $9.4B | — | ||
| Q4 25 | $9.4B | $3.3B | ||
| Q3 25 | $9.4B | $5.4B | ||
| Q2 25 | $9.5B | $5.0B | ||
| Q1 25 | $9.6B | $4.7B | ||
| Q4 24 | $9.7B | $4.8B | ||
| Q3 24 | $9.9B | $5.2B | ||
| Q2 24 | $10.0B | $5.0B |
| Q1 26 | $16.4B | — | ||
| Q4 25 | $16.6B | $15.5B | ||
| Q3 25 | $16.7B | $15.2B | ||
| Q2 25 | $16.5B | $14.5B | ||
| Q1 25 | $16.5B | $14.1B | ||
| Q4 24 | $16.5B | $14.2B | ||
| Q3 24 | $16.7B | $14.4B | ||
| Q2 24 | $16.8B | $14.2B |
| Q1 26 | 0.04× | — | ||
| Q4 25 | 0.59× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.52× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
WY
Segment breakdown not available.
ZTS
| Companion Animal | $1.5B | 67% |
| Livestock | $720.0M | 32% |
| Contract Manufacturing & Human Health | $23.0M | 1% |
